HEMGENIX: Transforming Hemophilia B Treatment with Long-Term Durability and Safety
Автор: The Daily Spectrum
Загружено: 2025-12-07
Просмотров: 7
Discover the groundbreaking results of the HOPE-B study, published in the New England Journal of Medicine. HEMGENIX, a one-time gene therapy, has shown remarkable durability and safety over five years. With 94% of patients free from continuous prophylaxis, this treatment offers a life-changing solution for adults with hemophilia B. Learn how HEMGENIX delivers sustained factor IX activity, reduces bleeding rates, and provides freedom from ongoing therapy. Join us as we explore the pivotal milestone in gene therapy and the potential it holds for transforming hemophilia care.
Доступные форматы для скачивания:
Скачать видео mp4
-
Информация по загрузке: